恩替卡韦血浆浓度负相关的HBV-DNA降低治疗初治患者慢性乙型

StephenW

Int J Antimicrob Agents. 2016 Jul 7. pii: S0924-8579(16)30154-6. doi: 10.1016/j.ijantimicag.2016.05.016. [Epub ahead of print]Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B.Boglione L1, De Nicolò A2, Cusato J2, Bonifacio G2, Cariti G2, Di Perri G2, D'Avolio A2.
Author information

• 1Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Ospedale Amedeo di Savoia, Turin, Italy. Electronic address: [email protected].
• 2Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Ospedale Amedeo di Savoia, Turin, Italy.
  

AbstractThe role of therapeutic drug monitoring (TDM) of entecavir (ETV) in the treatment of patients affected by chronic hepatitis B (CHB) has not yet been defined. Here we present an interim analysis regarding the role of ETV TDM in a prospective cohort of treatment-naïve patients with CHB who received this treatment. The results from 40 patients consecutively enrolled at our centre from 2010 to 2013 are described. The primary endpoint was the evaluation of the role of ETV plasma concentrations in the kinetics of hepatitis B virus (HBV) DNA decrease. Minimum ETV concentrations (Ctrough) were measured every month after the start of therapy for the first 3 months and then every 6 months. The main result of the pharmacokinetic analysis was the significant inverse correlation of ETV concentration after 1 month of treatment and HBV-DNA decrease after 3 months of treatment (r = -0.624; P <0.001). This correlation was also confirmed when stratifying patients on the basis of viral genotypes: A (r = -0.719; P = 0.003); C (r = -0.917; P = 0.007); and D (r = -0.760; P = 0.007). Possible explanations for this phenomenon could involve interpatient differences in liver conditions (tissue damage or inflammation) and/or genetic variability in specific drug transporters. Further investigations are needed to confirm these results quantifying ETV concentration in peripheral blood mononuclear cells as well as in a larger cohort.
Copyright © 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.


KEYWORDS: Entecavir; Hepatitis B; Plasma concentration; Therapeutic drug monitoring

PMID:27444118DOI:10.1016/j.ijantimicag.2016.05.016

StephenW

诠释J Antimicrob代理。 2016年7月PII：S0924-8579（16）30154-6。 DOI：10.1016 / j.ijantimicag.2016.05.016。 [打印EPUB提前]
恩替卡韦血浆浓度负相关的HBV-DNA降低治疗初治患者慢性乙型肝炎的队列
Boglione L1，德尼科洛A2，Cusato J2，博尼法乔G2，G2 Cariti迪PERRI G2，D'Avolio A2。
作者信息

    传染病1台，医学科学，都灵大学，Ospedale Amedeo大街萨沃亚，意大利都灵系。电子地址：[email protected]。
    传染病2Unit，医学科学，都灵大学，Ospedale Amedeo大街萨沃亚，意大利都灵系。

抽象

在受慢性乙型肝炎（CHB）的患者的治疗恩替卡韦（ETV）的治疗药物监测（TDM）的作用还没有被定义。这里我们介绍关于ETV的TDM与CHB谁接受这种治疗方法治疗初治患者的前瞻性队列中的作用的中期分析。从连续参加在我中心2010至2013年40例，结果进行了说明。主要终点是ETV血浆浓度的乙型肝炎病毒（HBV）DNA的减少的动力学的作用的评估。最小ETV浓度（Ctrough）进行每月测定治疗的最初3个月，然后每6个月后开始。药代动力学分析的主要结果是ETV浓度为1个月的治疗和HBV-DNA的下降后的3个月的治疗相关（r = -0.624; p <0.001）之后的显著逆相关。病毒基因型的基础上分层的患者时，该相关性也证实：A（R = -0.719; p = 0.003）; C（R = -0.917，P = 0.007）;和D（R = -0.760; p = 0.007）。对于这种现象的可能的解释可能涉及在肝条件特定药物转运患者间差异（组织损伤或炎症）和/或遗传变异。需要进一步的研究以证实这些结果定量外周血单核细胞，以及在更大范围内的队列ETV浓度。

版权所有©2016年爱思唯尔B.V.和化疗的国际协会。版权所有。
关键词：

恩替卡韦;乙型肝炎;血药浓度;治疗药物监测

结论：
    27444118
DOI：
    10.1016 / j.ijantimicag.2016.05.016